Sanofi’s HERCULES Data In MS May Offer Path To Approval For Tolebrutinib
Delaying disease progression in non-relapsing secondary multiple sclerosis may get the BTK inhibitor approved, despite previous pivotal trial failures in relapsing MS.
Delaying disease progression in non-relapsing secondary multiple sclerosis may get the BTK inhibitor approved, despite previous pivotal trial failures in relapsing MS.